Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent clostridium difficile-associated diarrhea

Journal of Clinical Gastroenterology

Volumn 44, Issue 5, 2010, Pages 354-360

  Khoruts, Alexander ^a   Dicksved, Johan ^b   Jansson, Janet K ^c   Sadowsky, Michael J ^d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

16S rRNA; Bacteriotherapy; Clostridium difficile; T RFLP

Indexed keywords

CEPHALOSPORIN; METRONIDAZOLE; NITAZOXANIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBOSOME RNA; VANCOMYCIN;

ADULT; ARTICLE; BACTERIAL STRAIN; CASE REPORT; CLOSTRIDIUM DIFFICILE INFECTION; COLON FLORA; CONTROLLED STUDY; FECES COMPOSITION; FECES MICROFLORA; FEMALE; FIRMICUTES; HUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RNA SEQUENCE;

CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; METAGENOME; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RNA, RIBOSOMAL, 16S; SEQUENCE ANALYSIS, RNA;

EID: 77951700268     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181c87e02     Document Type: Article

References (36)

1. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med. 2008;359:1932-1940.
2. Issa M, Vijayapal A, Graham MB, et al. Impact of clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:345-351.
3. Greenfield C, Aguilar Ramirez JR, Pounder RE, et al. Clostridium difficile and inflammatory bowel disease. Gut. 1983;24:713-717.
4. Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339-344.
5. Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. Cmaj. 2004;171:33-38.
6. Yearsley KA, Gilby LJ, Ramadas AV, et al. Proton pump inhibitor therapy is a risk factor for Clostridium difficileassociated diarrhoea. Aliment Pharmacol Ther. 2006;24: 613-619.
7. Spigaglia P, Mastrantonio P. Comparative analysis of Clostridium difficile clinical isolates belonging to different genetic lineages and time periods. J Med Microbiol. 2004;53: 1129-1136.
8. Lyerly DM, Krivan HC, Wilkins TD. Clostridium difficile: its disease and toxins. Clin Microbiol Rev. 1988;1:1-18.
9. Stabler RA, Dawson LF, Phua LT, et al. Comparative analysis of BI/NAP1/027 hypervirulent strains reveals novel toxin B-encoding gene (tcdB) sequences. J Med Microbiol. 2008;57: 771-775.
10. Surowiec D, Kuyumjian AG, Wynd MA, et al. Past, present, and future therapies for Clostridium difficile-associated disease. Ann Pharmacother. 2006;40:2155-2163.
11. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent clostridium difficile disease. Am J Gastroenterol. 2002;97:1769-1775.
12. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001;357:189-193.
13. Wilson KH. The microecology of Clostridium difficile. Clin Infect Dis. 1993;16:S214-S218.
14. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008;197:435-438.
15. Dicksved J, Floistrup H, Bergstrom A, et al. Molecular fingerprinting of the fecal microbiota of children raised according to different lifestyles. Appl Environ Microbiol. 2007; 73:2284-2289.
16. Dicksved J, Halfvarson J, Rosenquist M, et al. Molecular analysis of the gut microbiota of identical twins with Crohn's disease. ISME J. 2008;2:716-727.
17. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308: 1635-1638.
18. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet. 1989;1:1156-1160.
19. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36:580-585.
20. Schwan A, Sjolin S, Trottestam U, et al. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis. 1984;16:211-215.
21. Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol. 2000;95: 3283-3285.
22. Palmer C, Bik EM, DiGiulio DB, et al. Development of the human infant intestinal microbiota. PLoS Biol. 2007;5:e177.
23. Rolfe RD, Helebian S, Finegold SM. Bacterial interference between Clostridium difficile and normal fecal flora. J Infect Dis. 1981;143:470-475.
24. Jernberg C, Sullivan A, Edlund C, et al. Monitoring of antibiotic-induced alterations in the human intestinal microflora and detection of probiotic strains by use of terminal restriction fragment length polymorphism. Appl Environ Microbiol. 2005;71:501-506.
25. Dethlefsen L, Huse S, Sogin ML, et al. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6:e280.
26. Muyzer G, de Waal EC, Uitterlinden AG. Profiling of complex microbial populations by denaturing gradient gel electrophoresis analysis of polymerase chain reaction-amplified genes coding for 16S rRNA. Appl Environ Microbiol. 1993;59: 695-700.
27. Hjort K, Lembke A, Speksnijder A, et al. Community structure of actively growing bacterial populations in plant pathogen suppressive soil. Microb Ecol. 2007;53:399-413.
28. Edwards U, Rogall T, Blocker H, et al. Isolation and direct complete nucleotide determination of entire genes. characterization of a gene coding for 16S ribosomal RNA. Nucleic Acids Res. 1989;17:7843-7853.
29. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol. 1985;80:867-868.
30. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124:837-848.
31. Schwiertz A, Hold GL, Duncan SH, et al. Anaerostipes caccae gen. nov., sp. nov., a new saccharolytic, acetate-utilising, butyrate-producing bacterium from human faeces. Syst Appl Microbiol. 2002;25:46-51.
32. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesityassociated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027-1031.
33. Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444: 1022-1023.
34. Wachtershauser A, Stein J. Rationale for the luminal provision of butyrate in intestinal diseases. Eur J Nutr. 2000;39:164-171.
35. Roediger WE. The starved colon-diminished mucosal nutrition, diminished absorption, and colitis. Dis Colon Rectum. 1990;33:858-862.
36. Gustafsson A, Lund-Tonnesen S, Berstad A, et al. Faecal short-chain fatty acids in patients with antibiotic-associated diarrhoea, before and after faecal enema treatment. Scand J Gastroenterol. 1998;33:721-727.